Novartis Reveals Long-Term Data Of Atrophy Gene Therapy Exhibiting Sustained Durability Of Up To 7.5 Years

  • Novartis AG NVS has presented new data on Zolgensma (onasemnogene abeparvovec), a one-time gene therapy for the treatment of spinal muscular atrophy (SMA). 
  • The latest data from two Long-Term Follow-Up studies, LT-001 and LT-002, show the continued efficacy and durability of Zolgensma across a range of patient populations, with an overall benefit-risk profile that remains favorable.
  • Highlighting the remarkable durability of Zolgensma, data from LT-001, an ongoing 15-year study of patients who completed the Phase 1 START study, showed that up to 7.5 years post-dosing, children who were treated after presenting symptoms of SMA maintained all previously achieved motor milestones.
  • During LT-001, three additional patients also achieved the key milestone of “standing with assistance.”
  • Interim results from the 15-year LT-002 study, which includes both presymptomatic and symptomatic patient populations, were also presented. All patients (100%) maintained motor milestones achieved during their respective parent studies in the follow-up period.
  • Results from the IV cohort, which included 63 patients, demonstrated how a single administration of Zolgensma provided consistent, substantial, and durable efficacy over time. 
  • In the presymptomatic IV cohort (n=25), all children (100%) either maintained the highest milestone achieved during the parent study (walking alone) or achieved the milestone by the data-cut off. 
  • Six patients treated before SMA symptom onset and 16 treated after SMA symptom onset achieved new motor milestones in the follow-up period.
  • All 18 children in LT-002 treated with one-time investigational OAV101 IT were alive, free from permanent ventilation, and showed incremental gains in motor function as of the May 2022 data cut-off. 
  • Five of 16 patients with a milestone assessment achieved new milestones during the long-term follow-up period, such as crawling, walking, or standing with assistance.
  • Price Action: NVS shares are up 0.72% at $82.78 during the premarket session on the last check Monday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechLarge CapNewsHealth CareGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!